• NeoGenomics’ RaDaR ST MRD assay received expanded Medicare coverage under CMS’s MolDX program for immunotherapy response monitoring in late-stage solid tumors.
• Coverage adds a third reimbursed indication for RaDaR ST, alongside head and neck squamous cell carcinoma and a subset of HR+ HER2-negative breast cancer.
• Decision broadens reimbursement access for longitudinal ctDNA testing during systemic therapy, a potential driver of test utilization in advanced cancer care.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NeoGenomics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202608261617BIZWIRE_USPR_____20260826_BW891210) on August 26, 2026, and is solely responsible for the information contained therein.